Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

Vaccine

Volumn 21, Issue 19-20, 2003, Pages 2474-2484

  Ramiro, Maria J ^a   Zárate, Juan J ^b   Hanke, Tobias ^a   Rodriguez, Dolores ^c   Rodriguez, Juan R ^d   Esteban, Mariano ^c   Lucientes, Javier ^b   Castillo, Juan A ^b   Larraga, Vicente ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^d Bionostra   (Spain)

Author keywords

DNA; Dogs; LACK; Prime boost; Vaccination; Vaccinia virus vectors; Visceral leishmaniasis

Indexed keywords

ANTIGEN; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 12; INTERLEUKIN 4; MESSENGER RNA; PARASITE ANTIBODY; PROTEIN; PROTEIN LACK; PROTEIN P40; PROTEIN SUBUNIT; RECOMBINANT VACCINIA VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CARRIER; DISEASE COURSE; DOG; GENE; IMMUNIZATION; INFECTION PREVENTION; INOCULATION; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE; PARASITOSIS; PLASMID; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT OUTCOME; VACCINATION; VACCINIA; VISCERAL LEISHMANIASIS;

EID: 0037726800     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00032-X     Document Type: Article

References (52)

1. Rioux D., Lanotte G., Serres E., Prarlong F., Bastien P., Prieres J. Taxonomy in Leishmania: use of isoenzymes. Suggestions for a new classification. Ann. Parasitol. Hum. Comp. 65:1990;111-125.
2. Jimenez M.I., Gutierrez-Solar B., Benito A.et al. Cutaneous Leishmania infantum zymodemes isolated from bone marrow in AIDS patients. Res. Rev. Parasitol. 51:1991;91-95.
3. Dye C. The logic of visceral leishmaniasis control. Am. J. Trop. Med. Hyg. 55:1996;125-130.
4. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Ann. Rev. Immunol. 13:1995;151-177.
5. Locksley R.M., Reiner S.L., Hatam F., Litman D.R., Killen N. Helper T cells without CD4, control of leishmaniasis in CD4-deficient mice. Science. 261:1993;1448-1451.
6. Chackalat H.R., Theodor C.M., Markowitz J.S., Grusby M.J., Gkincher L.H., Titus R.G. Class II major histocompatibility complex deficient mice initially control an infection with Leishmania major but succumb to the disease. J. Infect. Dis. 171:1995;1302-1308.
7. + T-cells in intracellular infections in human: Leishmania as an example. Immunol. Today. 17:1996;13-16.
8. Paul W., Seder R.A. Lymphocyte responses and cytokines. Cell. 76:1994;241-251.
9. Gonzalo R.M., del Real G., Rodriguez J.R.et al. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum p36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine. 20:2002;1226-1231.
10. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today. 17:1996;138-146.
11. Biederman T., Zimmerman S., Himmelrich H.et al. IL-4 instructs Th1 responses and resistance to Leishmania major in susceptible Balb/c mice. Nat. Immunol. 11:2001;1054-1060.
12. Gradoni L. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet. Parasitol. 100:2001;87-103.
13. Dunan S., Frommel D., Monjour L., Oguncolade B.W., Cruz A., Quilici M. Vaccination trial against canine leishmaniasis. Parasite Immunol. 11:1989;397-402.
14. Pinelli E., Killick-Kendrick R., Wagenaar J., Bernardina W., del Real G., Ruittemberg J. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect. Immun. 62:1994;229-235.
15. Quinell R.J., Courtenay O., Shaw M.-A.et al. Tissue cytokine responses in canine visceral leishmaniasis. J. Infect. Dis. 183:2001;1421-1424.
16. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application and optimization. Ann. Rev. Immunol. 18:2000;927-974.
17. Xu D., Liew F.Y. Genetic vaccination against leishmaniasis. Vaccine. 12:1994;241-245.
18. Gurunathan S., Sacks D., Brown D.R.et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1997;1137-1147.
19. Gonzalo R.M., Rodriguez J.R., Rodriguez D., Gonzalez-Aseguiolaza G., Larraga V., Esteban M. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimen with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect. 3:2001;701-711.
20. Gonzalez-Aseguinolaza G., Taladriz S., Marquet A., Larraga V. Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum. Eur. J. Biochem. 259:1999;909-916.
21. Chackrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: co expression of β-galactosidase provides visual screening of recombinant virus plates. Mol. Cell. Biol. 5:1985;3403-3409.
22. Martinez-Moreno A., Martinez-Cruz M.S., Blanco A., Hernandez-Rodriguez S. Immunological histological study of T- and B-lymphocyte activity in canine visceral leishmaniasis. Vet. Parasitol. 51:1993;49-59.
23. Riera C., Valladares J.E., Gállego M.et al. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with menglumine antimoniate. Vet. Parasitol. 84:1999;33-47.
24. Evans D. Handbook on isolation characterization and cryopreservation of Leishmania. In: UNDP/world Bank/WHO special program for research and training in tropical diseases. 1989.
25. WHO. Manual on visceral leishmaniasis control. WHO/LEISH/96.40. Geneva (Switzerland):1996; p. 51-70.
26. Boelaert M., El Safi S., Mousa H.et al. Multi-centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasis. Trop. Med. Int. Health. 4(1):1999;31-37.
27. Boelaert M., El Safi S., Jacquet D., Van der Stuyf P., Le Ray D., De Muynck D. Operational validation of the direct agglutination test for diagnosis of visceral leishmaniosis. Am. J. Trop. Med. Hyg. 4(1):1999;129-134.
28. Boelaert M., El Safi S., Goetghebeur E., Gomes-Pereira S., Le Ray D., van der Stuyf P. Latent class analysis permits unbiased estimates of the validity of DAT for the diagnosis of visceral leishmaniasis. Trop. Med. Int. Health. 4(5):1999;395-401.
29. Baumann R.J., Hanson W.L., McCaan P.P., Sjodersma A., Bitonti A.J. Suppression of both antimony-susceptible and antimony-resistant Leishmania donovani by a bis(benzyl)polyamine analogue. Antimicrob. Agents Chemother. 34:1990;722-727.
30. Shifrine M., Taylor N.J., Rosenblat L.S., Wilson F.D. Comparison of whole blood and purified canine experimental leishmaniasis. Am. J. Vet. Res. 39:1978;441-449.
31. Huong P.L., Kolk A.H., Eggelte T.A., Verstignen C.P., Gilis H., Hendricks J.T. Measurement of antigen specific lymphocyte proliferation using 5-bromo-doxyuridine incorporation. An easy and low cost alternative to radioactive thymidine incorporation. J. Immunol. Methods. 140:1991;243-248.
32. Rottman J.B., Freeman E.B., Tonkonogy S., Tompkins M.B. A reverse transcription-polymerase chin reaction technique to detect fine cytokine genes. Vet. Immunol. Immunopathol. 45:1995;1-18.
33. Seah G.T., Scott G.M., Rook G.A.W. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J. Infect. Dis. 181:2000;385-389.
34. Almeida M.C. Infective inoculum for Leishmania. Trends Parasitol. 18:2002;154-155.
35. Fondevila D., Vilafranca M., Ferrer L. Epidermal immunocompetence in canine leishmaniasis. Vet. Immunol. Immunopathol. 56:1997;319-327.
36. Solano-Gallego L., Llul J., Ramos G.et al. The ibizian hound presents a predominantly cellular immune response against natural Leishmania infection. Vet. Parasitol. 90:2000;37-45.
37. Gherardi M., Ramírez J.C., Rodríguez D., Rodríguez J.R., Sano G., Zavala F.et al. IL-12 delivery from recombinant vaccinia virus attenuates vector infectivity and enhances cellular immune response against HIV-1 env in a dose-dependent manner. J. Immunol. 162:1999;6724-6734.
38. Zinkernagel R.M. Immunology taught by viruses. Science. 271:1996;173-178.
39. +-cell responses against malaria liver stages. Nat. Med. 8:2002;166-170.
40. Jankovic D., Liu Z., Gause W.C. Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol. 22:2001;450-457.
41. Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Trends Immunol. 21:2000;163-165.
42. Mougneau E., Altare F., Wakil A.et al. Expression cloning of a protective Leishmania antigen. Science. 268:1995;563-566.
43. Gurunathan S., Prussin C., Sacks D.L., Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4:1998;1409-1415.
44. Soussi N., Saklani-Jusforgues H., Colle J.H., Milon G., Glaichenhaus N., Grossens P.L. Effect of intragastic and intraperitoneal immunisation with atenuated and wild-type LACK-expressing Listeria monocytogenes on control murine Leishmania major infection. Vaccine. 20:2002;2702-2712.
45. Melby P.C., Yang J., Zhao W., Perez L.E., Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:2001;4719-4725.
46. Aguilar-Tormentera F., Glaichenhaus N., Laman J.D., Carlier Y. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility to BALB/c mice to Leishmania mexicana. Infect. Immun. 69:2001;617-621.
47. Maasho K., Satti I., Nylen S., Guzman G., Koning F., Akuffo A. A Leishmania homologue of receptors for activated C-kinase (LACK) induces both interferon-γ and interleukin-10 in natural killer cells of healthy blood donors. J. Infect. Dis. 182:2000;570-578.
48. Maasho K, Wolday D, Edjigu M, Soderstrom K, Britton S, Akuffo H. Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis, Cin Exp Immunol 2001;124:255-61.
49. De Luna R, Vuotto ML, Ielpo MTL, Ambrosio R, Piantedosi D, Moscatiello V, Ciaramella, P, Scalone A, Gradoni L, Mancino D. Early supression of lymphoproliferative response in dogs with natural infection by Leishmania infantum. Vet Immunol Immunopathol 1999;70:95-103.
50. + cells. J. Virol. 280:2001;155-159.
51. Rodriguez D., Rodriguez J.R., Llorente M.et al. A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine. J. Gen. Virol. 80:1999;217-223.
52. + antigen specific T cells. Infect. Immun. 67:1999;5559-5566.